Inotropic agents: raise cardiac output only when low output is causing harm
Positive inotropes increase the force of myocardial contraction. In modern practice they are mainly short-term, closely monitored IV medicines for cardiogenic shock or acute heart failure with hypotension and hypoperfusion—not routine treatment for a congested but adequately perfused patient. They can restore perfusion, but can also cause tachyarrhythmia, myocardial ischaemia and excess mortality if used unnecessarily or for too long.
This lesson connects the pharmacology to bedside decisions: identify low output, treat the cause, select the least harmful haemodynamic support, monitor continuously, and wean as soon as perfusion is stable.
1. Meaning, terminology and the clinical goal
Inotropy is the strength of cardiac contraction. A positive inotrope increases intracellular calcium availability or the contractile apparatus response to calcium, increasing stroke volume and cardiac output. Chronotropy changes heart rate; dromotropy changes conduction; lusitropy improves relaxation.
| Term | What it does | Example | Clinical warning |
|---|---|---|---|
| Inotrope | Increases contractility and cardiac output | Dobutamine, milrinone, digoxin | May provoke ischaemia/arrhythmia |
| Inodilator | Inotropy plus arterial/venous vasodilation | Milrinone, levosimendan | Can lower blood pressure |
| Vasopressor | Raises vascular tone and blood pressure | Norepinephrine | Does not by itself fix poor contractility |
| Chronotrope | Changes heart rate | Isoprenaline | Increased rate may raise oxygen demand |
2. First decide: does the patient truly need an inotrope?
Use an inotrope when there is evidence of low cardiac output with end-organ hypoperfusion, especially if accompanied by hypotension, despite correcting immediately reversible problems. Warning signs include cold clammy peripheries, oliguria, altered mental state, rising lactate/metabolic acidosis, narrow pulse pressure, weak pulses and pulmonary oedema with a low-output state.
Before starting: treat the cause in parallel
- Secure airway, oxygenation/ventilation and IV access; obtain ECG, blood pressure, urine output, glucose, electrolytes, renal function and lactate where available.
- Look for acute coronary syndrome, serious arrhythmia, mechanical complication, sepsis, pulmonary embolism, tamponade, acute valvular disease, severe anaemia, drug toxicity or fluid loss.
- Assess volume status. A hypotensive patient may need cautious fluid if genuinely hypovolaemic; fluid overload needs decongestion, not repeated blind boluses.
- In cardiogenic shock with marked hypotension, a vasopressor—often norepinephrine—may be needed to maintain perfusion pressure while an inotrope supports cardiac output.
Do not use an inotrope simply because the ejection fraction is low. A warm, adequately perfused patient with chronic HFrEF should receive guideline-directed therapy and diuretics as indicated, not continuous inotropic stimulation.
3. How contraction is increased: the calcium map
- Action potential opens L-type calcium channels during phase 2.
- Small calcium influx triggers larger calcium release from the sarcoplasmic reticulum (calcium-induced calcium release).
- Calcium binds troponin C, allowing actin–myosin cross-bridge cycling and contraction.
- Relaxation requires calcium reuptake into sarcoplasmic reticulum (SERCA) and extrusion via the Na+/Ca2+ exchanger.
Drugs increase contractility by one of four broad strategies: beta1 stimulation (dobutamine), PDE-3 inhibition (milrinone), Na+/K+-ATPase inhibition (digoxin), or calcium sensitisation (levosimendan). More calcium or cyclic AMP can improve output—but also increases arrhythmogenic risk and myocardial oxygen consumption.
4. Classification at a glance
Cardiac glycoside
Digoxin: positive inotrope, vagotonic AV-node slowing; long half-life and narrow therapeutic index.
Beta-adrenergic agonists
Dobutamine (mainly beta1), dopamine and adrenaline/epinephrine: rapid IV catecholamine support.
PDE-3 inhibitor
Milrinone: inodilator; useful when beta-blockade limits catecholamine response, but hypotension and renal accumulation matter.
Calcium sensitiser
Levosimendan: availability varies; an inodilator used in some settings with specialist monitoring.
5. Dobutamine
Mechanism: predominantly beta1-receptor agonism increases cAMP, calcium entry and contractility. It has some beta2/alpha effects, so the blood-pressure response is variable. It starts quickly and has a very short half-life; it is given by controlled IV infusion.
| Use | Typical adult ICU approach* | Important adverse effects | Practical point |
|---|---|---|---|
| Low-output acute HF/cardiogenic shock with adequate or supported BP; post-cardiac surgery; stress echo | Start low and titrate to perfusion, often 2–20 micrograms/kg/min IV infusion | Tachycardia, atrial/ventricular arrhythmias, hypertension or hypotension, angina/ischaemia, hypokalaemia | Response may be blunted by beta blockers; do not use as a routine long-term HF drug |
*Dose ranges are educational examples only: prescribe through local adult/paediatric protocols and use an infusion pump. Monitor ECG, heart rate, rhythm, BP, urine output, mental status and peripheral perfusion. The product label warns that marked increases in heart rate or systolic BP can occur; reducing the rate usually reverses the effect.
Avoid or use specialist judgement in obstructive hypertrophic cardiomyopathy, uncontrolled tachyarrhythmia, active ischaemia, severe hypovolaemia or uncorrected obstruction to outflow. Treat new tachyarrhythmia or ischaemic pain urgently; reduce/stop the infusion and call senior/critical-care support.
6. Milrinone: the classic inodilator
Mechanism: selective PDE-3 inhibition prevents cAMP breakdown in myocardium and vascular smooth muscle. The result is stronger contraction plus vasodilation, with reduced systemic/pulmonary vascular resistance and filling pressures. Unlike dobutamine, its action is not directly dependent on beta receptors.
When milrinone may be considered
Acute decompensated HFrEF or low-output states where an inodilator is appropriate, particularly when a patient is receiving beta blockade or has pulmonary hypertension/right-ventricular failure. It is not automatically safer than dobutamine: its vasodilation can worsen hypotension and it accumulates in renal impairment.
- Typical adult regimen: loading dose 50 micrograms/kg IV over 10 minutes may be used in some protocols, followed by 0.375–0.75 micrograms/kg/min infusion. Many unstable patients are started without a loading dose. Reduce maintenance dosing in renal impairment.
- Adverse effects: hypotension, ventricular/supraventricular arrhythmias, headache, thrombocytopenia and hypokalaemia.
- Never use as chronic oral “heart-strengthening” therapy: long-term oral PDE-3 inhibition increased mortality.
- Nursing alert: a falling BP after milrinone may reflect vasodilation; do not automatically increase the dose. Reassess perfusion, volume status and need for vasopressor support.
7. Digoxin: an inotrope with a different bedside role
Mechanism: digoxin inhibits the Na+/K+-ATPase. Intracellular sodium rises, reducing sodium–calcium exchange, so intracellular calcium rises and contraction strengthens. It also increases vagal tone and slows AV-node conduction.
| Useful role | Not the role | Key monitoring |
|---|---|---|
| Rate control in chronic atrial fibrillation, especially with HFrEF or sedentary patients; selected symptomatic HFrEF patients despite standard therapy | Rapid rescue drug for cardiogenic shock; first-line treatment for sinus rhythm HFrEF; rate control in AF with WPW/accessory pathway | Apical pulse/ECG, renal function, potassium, magnesium, calcium, interacting drugs and serum digoxin level when clinically indicated |
Safe use: dose is individualised by age, lean body weight, renal function and interacting medicines. Lower maintenance doses (for example 62.5–125 micrograms daily) are often needed in frail older adults or renal impairment. Do not teach one fixed dose as safe for every patient.
Early toxicity clues: anorexia, nausea, vomiting, diarrhoea, confusion, weakness, blurred/yellow vision, bradycardia or new arrhythmia. Predisposing factors are renal impairment, hypokalaemia, hypomagnesaemia, hypercalcaemia, hypothyroidism and drug interactions (notably amiodarone, verapamil/diltiazem, quinidine, macrolides and some antifungals). Loop/thiazide diuretics can indirectly increase toxicity through potassium loss.
Important contraindication: avoid digoxin in AF with Wolff–Parkinson–White syndrome because AV-node blockade can permit dangerous conduction over the accessory pathway. In suspected toxicity: withhold digoxin, obtain ECG/electrolytes/renal function and serum level at an appropriate time, correct potassium/magnesium carefully, and escalate for digoxin-specific antibody fragments in life-threatening toxicity.
8. Dopamine, adrenaline and levosimendan
- Dopamine: dose-dependent dopaminergic, beta1 and alpha activity. The old concept of “renal-dose dopamine” is not a kidney-protection strategy and should not be used for that purpose. It can cause tachyarrhythmia and vasoconstriction at higher doses.
- Adrenaline/epinephrine: beta and alpha agonist with inotropic and vasopressor effects. It is used in specific shock/resuscitation settings, but may cause marked tachycardia, lactate elevation and arrhythmias. Follow emergency/ICU protocols.
- Levosimendan: calcium sensitiser and vasodilator. It may improve haemodynamics without directly raising intracellular calcium, but availability, cost and local policy vary; hypotension and arrhythmia remain concerns.
9. Choosing dobutamine or milrinone: a practical comparison
| Feature | Dobutamine | Milrinone |
|---|---|---|
| Mechanism | Beta1-dominant catecholamine | PDE-3 inhibitor (inodilator) |
| On/off control | Very rapid; short half-life | Longer effect; accumulation in renal impairment |
| Blood pressure | Variable; may raise or lower | More likely to lower through vasodilation |
| Beta-blocker use | Effect may be reduced | May retain effect |
| Major risks | Tachycardia, ischaemia, arrhythmia | Hypotension, arrhythmia, renal accumulation |
There is no universal winner. Choice depends on BP, rhythm, renal function, beta-blocker exposure, pulmonary vascular resistance/right-ventricular failure, local availability and clinician expertise. Reassess frequently and use the lowest effective dose for the shortest necessary duration.
10. Monitoring checklist for nurses and students
Before, during, after
- Before: baseline ECG/rhythm, BP/MAP, HR, SpO2, capillary refill/peripheries, consciousness, urine output, fluid balance, potassium/magnesium/creatinine and lactate if available.
- During: continuous ECG; frequent BP (preferably invasive in shock); infusion-pump verification; assess perfusion, chest pain, dyspnoea, lung findings, urine output and IV site.
- After any dose change: document time, dose, haemodynamic response and adverse effects. Reassess the need to continue rather than allowing an infusion to run by default.
- Weaning: when perfusion and the underlying problem improve, taper according to senior/ICU plan; watch for recurrence of hypotension, congestion or low output.
Extravasation: catecholamines can injure tissue. Use a reliable large vein/central access when indicated, inspect the site, stop infusion if infiltration is suspected and follow the local extravasation protocol immediately.
11. High-yield safety rules
- Cold + hypotensive + oliguria + rising lactate = suspect cardiogenic shock and escalate urgently.
- Inotropes improve haemodynamics; they do not replace reperfusion, rhythm correction, source control, surgery or mechanical support where those are needed.
- Do not equate more urine with “renal-dose dopamine working.” Treat the cause of hypoperfusion.
- Hypokalaemia makes digoxin more dangerous; correct electrolytes and review diuretics.
- In a hypotensive patient, an inodilator can worsen BP. Think “contractility + vascular tone,” not only “heart strength.”
- All inotropes deserve ECG and haemodynamic monitoring; they are not routine ward medicines.
12. Quick clinical checks
Case 1
A patient with acute MI is cold, confused, BP 78/45 mmHg and has pulmonary oedema. Answer: urgent critical-care/cardiology escalation; assess cardiogenic shock, support perfusion with protocolled vasoactive therapy and treat the cause (including reperfusion when indicated).
Case 2
An older patient on furosemide and digoxin develops nausea, yellow vision and bradycardia. Answer: suspect digoxin toxicity; withhold and urgently check ECG, potassium/magnesium, renal function and digoxin level.
Case 3
Milrinone is started and MAP falls. Answer: recognise vasodilation; reassess the patient and do not reflexively increase the inotrope.
References and further reading
- Supplied class reference: Inotropic Agents, Kirtan Bhatt (SlideShare).
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
- DailyMed prescribing information: dobutamine, milrinone and digoxin.
Educational resource for health-professions learners. It does not replace local protocols, senior review, medicine labels or patient-specific prescribing decisions.
